NTRK Gene Fusion - Laboratory Test Directory

Interface Order Alias

1230897

Clinical Information

Tissue sections were examined by pathological review for relevant tumor area for analysis. RNA sequencing was performed using Archer® FusionPlex platform on Illimina MiSeq to detect NTRK1, NTRK2 and NTRK3 gene fusions with different breakpoints and fusion partners. TKIs that inhibit tropomyosin receptor kinase (TRK) may be considered in patients with NTRK gene fusion positive disease. The lower limit of detection (LLOD) for NTRK RNA fusion is 5-10%. False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue

Ordering Instructions

Order Tissue Pathology [LAB8] in addition to NTRK Gene Fusion [LAB1230897]

Collection Instructions

Specimen Collection: Paraffin Block

Container(s): Formulin

Collection Instructions:

Place specimen in 10% Formalin and order Tissue Pathology [LAB8] in addition to NTRK Gene Fusion

Processing Instructions (Laboratory, Outpatient or Off-site collection)

Processed Specimen: FFPE

Transport Temperature: Ambient (Room Temperature)

Specimen Requirements

Remove: This field going away

Rejection Criteria

Quantity Not Sufficient (QNS) tissue for testing

Specimen Stability

Ambient

Test Frequency

Available once per week, usual TAT less than 7 days

Reference Range

An interpretive report will be provided.

Performing Department

Molecular Diagnostics

Performing Department Laboratory Location

Corewell Health Advanced Technology Laboratory (ATL), Grand Rapids, MI

Methodology

RNA sequencing was performed using Archer® FusionPlex platform on Illimina MiSeq

CPT

81194

CDM Code

Unavailable

Epic Test ID

1230102564

LOINC

Currently Unavailable

Mayo Access Code